Business Description
Astellas Pharma Inc
ISIN : US04623U1025
Share Class Description:
FRA:YPHA: ADRTotal Employee Number:
13,643Description
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.51 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | 0.97 | |||||
Interest Coverage | 27.01 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 2.73 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.7 | |||||
3-Year EBITDA Growth Rate | 34 | |||||
3-Year EPS without NRI Growth Rate | 43.7 | |||||
3-Year FCF Growth Rate | 26.4 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -4.77 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.87 | |||||
9-Day RSI | 50.52 | |||||
14-Day RSI | 48.39 | |||||
3-1 Month Momentum % | -13.43 | |||||
6-1 Month Momentum % | 4.5 | |||||
12-1 Month Momentum % | 44.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.17 | |||||
Quick Ratio | 0.9 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 281.32 | |||||
Days Sales Outstanding | 120.42 | |||||
Days Payable | 161.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.77 | |||||
Dividend Payout Ratio | 0.24 | |||||
3-Year Dividend Growth Rate | 9.1 | |||||
Forward Dividend Yield % | 3.77 | |||||
5-Year Yield-on-Cost % | 7.04 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 8.39 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.91 | |||||
Operating Margin % | 17.77 | |||||
Net Margin % | 13.63 | |||||
EBITDA Margin % | 27.36 | |||||
FCF Margin % | 22.08 | |||||
OCF Margin % | 26.05 | |||||
ROE % | 17.78 | |||||
ROA % | 8.43 | |||||
ROIC % | 9.52 | |||||
3-Year ROIIC % | 17.71 | |||||
ROC (Joel Greenblatt) % | 71.83 | |||||
ROCE % | 17.35 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.41 | |||||
Forward PE Ratio | 10.74 | |||||
PE Ratio without NRI | 13.56 | |||||
Shiller PE Ratio | 25.08 | |||||
Price-to-Owner-Earnings | 11.43 | |||||
PEG Ratio | 0.88 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 2.13 | |||||
Price-to-Tangible-Book | 10 | |||||
Price-to-Free-Cash-Flow | 8.22 | |||||
Price-to-Operating-Cash-Flow | 6.98 | |||||
EV-to-EBIT | 10.68 | |||||
EV-to-Forward-EBIT | 11.26 | |||||
EV-to-EBITDA | 7.13 | |||||
EV-to-Forward-EBITDA | 9 | |||||
EV-to-Revenue | 1.95 | |||||
EV-to-Forward-Revenue | 2.28 | |||||
EV-to-FCF | 8.78 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Projected-FCF | 0.94 | |||||
Price-to-Median-PS-Value | 0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.15 | |||||
Price-to-Graham-Number | 2.45 | |||||
Earnings Yield (Greenblatt) % | 9.36 | |||||
FCF Yield % | 12.2 | |||||
Forward Rate of Return (Yacktman) % | 17.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Astellas Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12,117.282 | ||
| EPS (TTM) (€) | 0.921 | ||
| Beta | 0.5013 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.38 | ||
| Volatility % | 34.84 | ||
| 14-Day RSI | 48.39 | ||
| 14-Day ATR (€) | 0.212124 | ||
| 20-Day SMA (€) | 11.175 | ||
| 12-1 Month Momentum % | 44.1 | ||
| 52-Week Range (€) | 7.75 - 14.1 | ||
| Shares Outstanding (Mil) | 1,791.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Astellas Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Astellas Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| USD 0.243791 Cash Dividend | 2026-03-31 | 13.40 (+0.00%) | ||
| USD 0.251450 Cash Dividend | 2025-09-30 | 8.85 (+0.00%) | ||
| USD 0.257267 Cash Dividend | 2025-03-31 | 8.80 (+0.00%) | ||
| USD 0.246724 Cash Dividend | 2024-09-30 | 10.20 (+0.00%) |
Show
Entries
Astellas Pharma Inc Frequently Asked Questions
What is Astellas Pharma Inc(FRA:YPHA)'s stock price today?
The current price of FRA:YPHA is €11.30. The 52 week high of FRA:YPHA is €14.10 and 52 week low is €7.75.
When is next earnings date of Astellas Pharma Inc(FRA:YPHA)?
The next earnings date of Astellas Pharma Inc(FRA:YPHA) is .
Does Astellas Pharma Inc(FRA:YPHA) pay dividends? If so, how much?
The Dividend Yield %  of Astellas Pharma Inc(FRA:YPHA) is 3.77% (As of Today), Highest Dividend Payout Ratio of Astellas Pharma Inc(FRA:YPHA) was 12.12. The lowest was 0.24. And the median was 0.57. The  Forward Dividend Yield % of Astellas Pharma Inc(FRA:YPHA) is 3.77%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Astellas Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers